ACRV - CIK 0001781174
The table below shows Acrivon Therapeutics, Inc.'s income statement line items across its last 5 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | - | - | - | - | - |
| Cost of revenue | - | - | - | - | - |
| Gross profit | - | - | - | - | - |
| R&D | $59.99M | $63.99M | $46.02M | $23.95M | - |
| SG&A | $24.12M | $25.21M | $21.08M | $8.71M | - |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| Operating income |
| -$84.11M |
| -$89.20M |
| -$67.10M |
| -$32.66M |
| -$16.18M |
| Income tax | $0.00 | - | - | - | - |
| Net income | -$77.91M | -$80.56M | -$60.39M | -$31.17M | -$16.24M |
| EPS (diluted) | -$2.02 | -$2.38 | -$2.74 | -$7.56 | -$9.32 |